王利杰?张慧芳?李桂英

    【摘要】糖尿病肾病(DN)是糖尿病患者严重的微血管并发症，是引发终末期肾脏病的常见病因。DN的发病机制复杂，目前对DN的治疗尚无突破性进展。近年来出现的胰高血糖素样肽-1(GLP-1)作为一种新型降糖药不仅在降糖方面有优势，而且能影响DN的发生发展。GLP-1类似物利拉鲁肽通过抑制内质网应激、调节内皮细胞生长因子、延缓足细胞损伤、抑制炎症及氧化应激、调节自噬对肾脏起到保护作用，该文就相关研究进行综述，以期为DN治疗方案的选择提供新的思路。

    【关键词】利拉鲁肽;糖尿病肾病;胰高血糖素样肽-1;内皮细胞;足细胞;氧化应激;

    自噬

    Research progress on the effect of GLP-1 analogue liraglutide on diabetic nephropathy Wang Lijie， Zhang Huifang， Li Guiying. Medical College， Hebei University of Engineering， Handan 056038， China

    Corresponding author， Li Guiying， E-mail： fflgy@ 126. com

    【Abstract】Diabetic nephropathy (DN) is a severe microvascular complication of diabetes mellitus and a common cause of end-stage renal disease.The pathogenesis of DN is complex. At present， no groundbreading progress has been achieved in treating DN. In recent years， glucagon-like peptide-1 (GLP-1)， as a new type of hypoglycemic agent， not only has advantages in reducing blood glucose level， but also affects the incidence and development of DN. GLP-1 analogue liraglutide can protect the kidney by inhibiting endoplasmic reticulum stress ......